Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-024287
Filing Date
2021-06-16
Accepted
2021-06-16 19:38:34
Documents
2
Period of Report
2021-06-16

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2176
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4727
  Complete submission text file 0000899243-21-024287.txt   8213
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address
Rozen Israel (Reporting) CIK: 0001867077 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40489 | Film No.: 211022926